There was no statistically significant difference in MNBI between Barrett’s while on or off PPIs (p=0.556). There was also no difference in MNBI between 9 patients with persistent Barrett’s who had attempted ablation therapy compared to the 13 who had not (p=0.96). Using the Kruskall-Wallace test, there was a significant difference observed in MNBI between all 3 categories of reflux (p<0.0001). Specifically, there was a difference in patients with Barrett’s (median MNBI 429.5± (293±950)¿ compared to NERD (116±6±(96±.5±27±64)¿ (p=0.003) and FH (335±5±(2866.5±2809.25)¿ (p=0.0001). There was also a significant difference in patients with NERD compared to FH (p<0.0001).

There was a moderately inverse correlation between Barrett’s segment length (median 6 cm (3 cm, 10 cm) and MNBI (r = 0.436; p=0.038).

Conclusion In keeping with the published literature, this study confirmed that severity of reflux disease, as measured by ambulatory pH-impedance monitoring, was not dissimilar between Barrett’s oesophagus and NERD, while symptom burden was greater in NERD. On the other hand, MNBI can differentiate between the disease states despite the reduced symptom burden. It also correlates with the degree of mucosal damage associated with Barrett’s regardless of PPI use or previous therapy. MNBI may be a better marker of reflux disease severity than standard pH measurements.

**VARIATION IN CELL CYCLE MARKERS IN BARRETT’S OESOPHAGUS IN RELATION TO CIRCUMFERENTIAL AND AXIAL LOCATION**


Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich, UK

10.1136/gutjnl-2019-BSGAbstracts.258

**Abstract PTU-044**

**Introduction** Reflux oesophagitis and early cancer in Barrett’s oesophagus (BO) have been reported to occur more frequently in the 12 to 3 o’clock position at the gastro-oesophageal junction. We analysed markers of proliferation, the cell cycle and inflammation in different circumferential and axial locations in subjects with BO to further study these observations.

**Methods** A prospective cohort study of adult subjects with BO undergoing endoscopic surveillance between December 2013 and July 2016 had quadrantic biopsies taken every 2 cm of the Barrett’s segment, with the circumferential location recorded for the most distal (gastro-oesophageal junction) and proximal biopsies (where 12 o’clock correlates to the gastric lesser curve). Two histopathologists (blinded to biopsy site) reported the degree of expression of various immunohistochemical markers for each biopsy site – p53, Ki67, cyclin D1, COX-2, and p21. Chi square analysis was performed to identify any association between biopsy site location and the degree of expression of the different cell markers.

**Results** 112 subjects were included: mean age 62.8 (SD 12.4) years; 78% male; median Barrett’s segment length 5.5 cm with 16% of neoplasia occurring in short (≤3 cm) segment Barrett’s. Lesion characteristics were similar between the two groups, except increased scarring in ≥75 group (table 1). R0 resection rate was 70.6% in ≥75 group and 77.9% in <75 group, with only 3.9% of ≥75 group and 5.3% of <75 group proceeding to surgery or chemoradiotherapy for residual or recurrent neoplasia. Complications occurred in 5.9% of ≥75 group (1 perforation, 2 bleeds) and 4.2% of <75 group (4 strictures), all of which were endoscopically managed. 3.9% of ≥75 group and 15.8% of <75 group proceeded to surgery following poor prognostic histology and overall 80.8% of all patients continued with sole endoscopic management.

**Abstract PTU-045**

**DOES AGE MATTER? ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR EARLY BARRETT’S NEOPLASIA**

Sophie Arndtz*, Shamila Subramaniam, Ejaz Hossain, Mohamed Adel Khalim, Pradeep Bhandari, Queen Alexandra Hospital, Portsmouth, UK

10.1136/gutjnl-2019-BSGAbstracts.259

**Aims** ESD is an established therapeutic option for the management of early Barrett’s neoplasia, offering superior en-bloc and R0 resection rates compared to endoscopic mucosal resection. However, ESD is thought to have a higher complication rate, due to the increased complexity of the procedure. The aim of our study was to evaluate the safety and efficacy of ESD for Barrett’s neoplasia in an ageing Western population.

**Methods** We performed a retrospective analysis of all ESDs conducted for Barrett’s neoplasia within a single tertiary referral centre in the UK from 2012–2018. Older patients were defined as ≥75 years of age and younger patients <75 years of age at time of procedure.

**Results** 146 of 316 Barrett’s resections were ESDs, of which 51 were ≥75 years and 95 <75 years. Overall age range was 42–94 years and mean follow up was 3.5 years. Average Barrett’s length was 5.5 cm with 16% of neoplasia occurring in short (≤3 cm) segment Barrett’s. Lesion characteristics were similar between the two groups, except increased scarring in ≥75 group (table 1). R0 resection rate was 70.6% in ≥75 group and 77.9% in <75 group, with only 3.9% of ≥75 group and 5.3% of <75 group proceeding to surgery or chemoradiotherapy for residual or recurrent neoplasia. Complications occurred in 5.9% of ≥75 group (1 perforation, 2 bleeds) and 4.2% of <75 group (4 strictures), all of which were endoscopically managed. 3.9% of ≥75 group and 15.8% of <75 group proceeded to surgery following poor prognostic histology and overall 80.8% of all patients continued with sole endoscopic management.

**Abstract PTU-045 Table 1** Pre-resection characteristics of the 146 ESDs

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Mean lesion size (mm)</th>
<th>En bloc resection n (%)</th>
<th>Previous resection (scarring) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥75</td>
<td>81</td>
<td>31</td>
<td>48 (94)</td>
</tr>
<tr>
<td>&lt;75</td>
<td>65</td>
<td>33</td>
<td>90 (95)</td>
</tr>
<tr>
<td>Total</td>
<td>70</td>
<td>32</td>
<td>138 (95)</td>
</tr>
</tbody>
</table>